FibroBiologics, Inc.

FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for chronic diseases with significant unmet medical needs ¹. The company was formed in April 2021 as FibroBiologics, LLC, and converted to a Delaware corporation in December 2021, changing its name to FibroBiologics, Inc. on April 12, 2023 ². Its operations have primarily involved corporate and strategic planning, personnel recruitment, financing, intellectual property management, and preclinical and other research and development activities related to its product candidates ³. The company has incurred significant net losses since inception and has not generated any revenue from product sales to date ⁴.

The core business model revolves around leveraging fibroblast cells as a technology platform for regenerative medicine. Fibroblasts are highlighted as favorable to stem cells for cell therapy due to their non-invasive harvesting from skin donors, faster doubling time, superior immune modulatory activity, differentiated state preventing spontaneous differentiation, enhanced production of regenerative cytokines and growth factors, and more economical isolation, culture, and expansion ⁵. The company's primary customer segments, once products are commercialized, would be patients suffering from chronic diseases such as wound healing, multiple sclerosis, degenerative disc disease, and psoriasis ⁶.

FibroBiologics has a pipeline of product candidates at various stages of development. CYWC628 is being developed as a topically administered allogeneic fibroblast cell-based therapy for wound healing, with IND-enabling preclinical studies completed showing statistically significant acceleration in wound closure and improvement in healed wound quality compared to a marketed product and control ⁷. The company plans to initiate a twelve-week Phase 1/2 clinical trial in Australia for diabetic foot ulcers in the first quarter of 2026 ⁸. The global wound care market was valued at approximately $21.0 billion in 2024 and is projected to grow to approximately $35.9 billion by 2032 ⁹.

CYMS101 is an intravenously administered allogeneic fibroblast single cell and spheroid cell-based therapy for multiple sclerosis (MS). A Phase 1 study in Mexico with five participants showed no adverse events related to treatment and general improvement in Paced Auditory Serial Addition Test (PASAT) and Nine-Hole Peg test scores ¹⁰. The company plans to file an IND application for a Phase 1/2 clinical trial in the United States in the first half of 2026 and expects to seek a strategic partner for its development ¹¹. The MS drug market was valued at approximately $21.3 billion globally in 2023, with North America representing approximately 48% of the market share, and is projected to grow to approximately $38.9 billion globally by 2032 ¹².

CybroCell™ is an investigational intradiscal administered allogeneic fibroblast cell-based therapy for degenerative disc disease, designed to repair intervertebral disc cartilage. Two animal studies in rabbit models demonstrated that neonatal human dermal fibroblasts (nHDFs) increased disc height index by 10% after eight weeks (p < .05) in the first study and 7.8% (p < .01) in the second study, compared to controls ¹³. The company received IND clearance from the FDA in 2018, conditional upon master cell bank approval, for a planned clinical trial ¹⁴. The degenerative disc disease treatment market was valued at approximately $26.1 billion globally in 2021, with North America representing approximately 36.0% of the market share, and is projected to grow to $45.9 billion globally by 2029 ¹⁵.

CYPS317 is an allogeneic intravenously administered fibroblast spheroid cell-based investigational therapeutic for psoriasis. Preliminary IND-enabling preclinical studies in mouse models showed significant improvement with single and multiple administrations of fibroblast spheroids ¹⁶. A Phase 1/2 Investigational New Drug (IND) application was filed with the U.S. FDA on December 30, 2025, to initiate clinical trials ¹⁷. The psoriasis treatment market was valued at approximately $20.3 billion in North America in 2024 and is projected to grow to $42.6 billion by 2032 ¹⁸. The company also has early-stage research programs for human longevity (CYTER915 for thymic involution reversal), certain cancers (TCB190), and artificial pancreatic organoids ¹⁹.

For the fiscal year ended December 31, 2025, FibroBiologics reported total operating expenses of $16,649 thousand ²⁰, resulting in a loss from operations of $(16,649) thousand ²¹. Net loss for the year was approximately $18.6 million ²². As of December 31, 2025, the company had cash and cash equivalents of approximately $4.9 million ²³ and an accumulated deficit of approximately $54.2 million ²⁴.

Comparing fiscal year 2025 to 2024, research and development expenses increased by $2,903 thousand, from $4,504 thousand in 2024 to $7,407 thousand in 2025 ²⁵. General, administrative and other expenses remained relatively flat, increasing by $9 thousand from $9,233 thousand in 2024 to $9,242 thousand in 2025 ²⁶. Total operating expenses increased by $2,912 thousand, from $13,737 thousand in 2024 to $16,649 thousand in 2025 ²⁷. The net loss increased from approximately $11.2 million in 2024 to $18.6 million in 2025 ²⁸. Other income/(expense) saw significant changes, including a decrease in the fair value of warrant liability by $(5,385) thousand (from $5,385 thousand in 2024 to $0 in 2025) ²⁹, a change in fair value of forward contract liability by $417 thousand (from $(417) thousand in 2024 to $0 in 2025) ³⁰, a change in fair value of SEPA put option liability by $812 thousand (from $(460) thousand in 2024 to $352 thousand in 2025) ³¹, and a change in fair value of convertible debt by $(2,005) thousand (from $232 thousand in 2024 to $(1,773) thousand in 2025) ³². Commitment fee expenses decreased by $2,191 thousand (from $(2,191) thousand in 2024 to $0 in 2025) ³³, and placement agent and tail fee expenses decreased by $1,450 thousand (from $(1,450) thousand in 2024 to $0 in 2025) ³⁴.

During the reported period, the manufacturing of the master cell bank and working cell bank for CYWC628 was completed and certified as released by the CDMO ³⁵. The company successfully demonstrated the ability to use the CYWC628 spheroid master cell bank for manufacturing a modified CybroCell™ drug product, supporting IND clearance with the FDA for a planned Phase I clinical trial ³⁶. An IND application for a Phase 1/2 clinical trial relating to MS in the United States is planned for the first half of 2026 ³⁷. On December 30, 2025, a Phase 1/2 Investigational New Drug (IND) application for CYPS317 was filed with the U.S. FDA ³⁸. The company also entered into a standby equity purchase agreement (SEPA) on December 20, 2024, with YA II PN, LTD., under which Yorkville advanced $15 million in convertible promissory notes, and the company may elect to sell up to $10 million worth of common stock until December 20, 2026 ³⁹. On January 7, 2025, 118,991 shares of common stock were issued to Yorkville to satisfy a commitment fee ⁴⁰.

FibroBiologics expects to continue incurring significant losses for the foreseeable future, with these losses projected to increase substantially as the company advances its product candidates through clinical development and towards commercialization, advances preclinical programs into clinical development, incurs manufacturing costs for cell production, seeks regulatory approvals, increases research and development activities, hires additional personnel, expands operational, financial, and management systems, meets public company requirements, invests in intellectual property, establishes sales, marketing, medical affairs, and distribution infrastructure, and expands manufacturing and commercialization efforts ⁴¹. The company's ability to generate significant revenue and achieve profitability will depend heavily on the development, approval, and subsequent commercialization of its product candidates ⁴².

A major growth area for FibroBiologics is the advancement of its lead product candidate, CYWC628, for wound healing. Based on positive preclinical study results showing statistically significant acceleration in wound closure and improved quality of healed wounds, the company plans to initiate a twelve-week Phase 1/2 clinical trial in Australia for the treatment of diabetic foot ulcers in the first quarter of 2026 ⁴³. This trial aims to generate reliable pivotal data for future approvals. The global wound care market, valued at approximately $21.0 billion in 2024, is projected to grow to approximately $35.9 billion by 2032, driven by increasing prevalence of chronic diseases and government initiatives to raise awareness and improve reimbursement policies ⁴⁴.

Another significant growth area is the development of CYMS101 for Multiple Sclerosis. Following a successful Phase 1 safety study in Mexico, the company is conducting further research to characterize the mode of action of fibroblasts in oligodendrocyte expansion ⁴⁵. FibroBiologics plans to file an IND application for a Phase 1/2 clinical trial in the United States in the first half of 2026 ⁴⁶. The company expects to seek a strategic partner for the development of CYMS101 either before or after the Phase 1/2 study, prior to a potential Phase 3 clinical trial ⁴⁷. The MS drug market, valued at approximately $21.3 billion globally in 2023, is projected to reach approximately $38.9 billion globally by 2032, with increasing investments in novel therapeutics and government initiatives to improve access to treatments ⁴⁸.

For CybroCell™ in degenerative disc disease, the company has completed two positive animal studies and received IND clearance from the FDA in 2018, conditional on master cell bank approval ⁴⁹. The company will work to amend the IND clearance to replace single-cell fibroblasts with fibroblast-derived chondrocyte spheroids derived from the CYWC628 master cell bank, with a trial timeline to be determined through discussions with the FDA ⁵⁰. The degenerative disc disease treatment market, valued at approximately $26.1 billion globally in 2021, is projected to grow to $45.9 billion globally by 2029 ⁵¹. Additionally, the company filed a Phase 1/2 IND application with the U.S. FDA on December 30, 2025, for CYPS317 for psoriasis, a market valued at approximately $20.3 billion in North America in 2024 and projected to grow to $42.6 billion by 2032 ⁵².

Operationally, the company expects to rely on third parties for its cell therapy manufacturing process for the foreseeable future, but will evaluate the feasibility of building its own cGMP manufacturing facility if any product candidates receive marketing approval ⁵³. The company plans to accelerate its early-stage research programs for human longevity, certain cancers, and artificial pancreatic organoids as funding allows ⁵⁴.

The company's future funding requirements will depend on factors such as the initiation, progress, timeline, cost, and results of clinical trials and preclinical studies, manufacturing activities, costs of acquiring or licensing additional assets, expansion of development programs, regulatory review outcomes, intellectual property costs, ability to establish collaborations, competitive developments, licensing and milestone payments, pricing and reimbursement, general operating expenses, commercialization costs, macroeconomic trends, and supply chain issues ⁵⁵. As of December 31, 2025, the company had approximately $4.9 million in cash and cash equivalents ⁵⁶. The company plans to raise additional capital through public or private equity offerings, debt financings, and/or potential collaborations and license arrangements ⁵⁷.

The company has identified structural headwinds and execution risks, including substantial doubt about its ability to continue as a going concern due to recurring operating losses and negative cash flows ⁵⁸. The company has a limited operating history and none of its product candidates have been approved for commercial sale, making future success and viability difficult to predict ⁵⁹. The regulatory approval processes are lengthy, time-consuming, and unpredictable, with no guarantee of obtaining approval for any product candidates ⁶⁰. Delays in clinical trials are a significant risk, potentially caused by regulatory disagreements, recruitment challenges, manufacturing issues, or adverse events ⁶¹. The outcome of preclinical studies or early clinical trials may not be predictive of later success, and interim data is subject to change ⁶². The company's refrigerated product candidates require specific distribution, storage, handling, and administration, which could limit commercial opportunity ⁶³. The novel nature of cell therapy and the evolving regulatory landscape pose additional complexities and uncertainties ⁶⁴.

Geographically, the company's contemplated twelve-week Phase 1/2 clinical trial for diabetic foot ulcers will be conducted in Australia, exposing it to business, political, operational, and financial risks associated with international operations, including differing laws, regulatory requirements, and potential difficulties in obtaining and enforcing intellectual property rights ⁶⁵. The acceptance of foreign clinical trial data by the FDA, EMA, or other regulatory authorities is subject to conditions and may require additional trials if not accepted ⁶⁶. Unfavorable global economic and geopolitical conditions, including tariffs, trade tensions, inflation, and disruptions to financial markets, could adversely affect the business ⁶⁷.

FibroBiologics faces substantial doubt about its ability to continue as a going concern due to recurring operating losses and negative cash flows since inception, with net losses of $18.6 million in 2025 and an accumulated deficit of $54.2 million as of December 31, 2025 ⁶⁸. The company will require substantial additional capital to finance operations, and failure to raise funds on acceptable terms could force delays or elimination of research and development programs ⁶⁹. The regulatory approval processes are lengthy, time-consuming, and inherently unpredictable, with no guarantee of obtaining approval for any product candidates, which would prevent product revenue generation ⁷⁰. Clinical trials are expensive, difficult to design, and uncertain, with the outcome of preclinical or early clinical trials not predictive of later success, and interim data subject to material changes ⁷¹. Product candidates may cause adverse events or undesirable side effects, potentially leading to clinical trial interruptions, delays, or denials of regulatory approval, or restrictive labeling ⁷². The company has limited experience in designing clinical trials and commercializing fibroblast cell-based therapies, and may lack the necessary expertise and resources ⁷³. Significant competition exists from companies with greater financial, manufacturing, marketing, and technical resources, which could negatively impact commercial opportunities if competitors develop more effective, safer, or less expensive products ⁷⁴. Manufacturing cell therapy products is complex and subject to human and systemic risks, including production difficulties, sourcing issues, and supply constraints of critical components, which could delay clinical trials or product supply ⁷⁵. The company's relationships with healthcare professionals and third-party payors are subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting, and health information privacy and security laws, with potential for criminal sanctions, civil penalties, and exclusion from government programs for non-compliance ⁷⁶. Evolving global data protection laws, such as the GDPR and state-specific privacy laws, may require substantial compliance costs and could result in significant fines and penalties for failure to comply ⁷⁷. The business entails significant product liability risks, and the company currently does not maintain clinical trial or product liability insurance in the United States, which could lead to substantial liabilities ⁷⁸. Intellectual property protection is uncertain, with risks that patent applications may not result in issued patents, issued patents may be challenged or invalidated, or competitors may design around patents, potentially diminishing competitive advantage ⁷⁹. The company is subject to export and import controls, economic sanctions, and anti-corruption laws, with violations potentially leading to substantial civil and criminal fines ⁸⁰. Unfavorable global economic and geopolitical conditions, including tariffs, trade tensions, inflation, and disruptions to financial markets, could adversely affect the business ⁸¹.

Management's overall tone emphasizes a commitment to becoming a world leader in regenerative medicine through a rigorous scientific process and dedication to patient needs, leveraging their fibroblast technology platform ⁸². They acknowledge the significant financial challenges, including recurring operating losses and negative cash flows, and the need for substantial additional funding to continue operations and research and development efforts ⁸³. Strategic priorities include prioritizing clinical development for product candidates addressing significant unmet needs, partnering with Clinical Research Organizations (CROs) for trial execution, attracting and retaining skilled scientists, investing in manufacturing capabilities, protecting and expanding intellectual property, and expanding development efforts for product candidates with longer timelines as funding permits ⁸⁴. Specific forward-looking statements include the plan to initiate a twelve-week Phase 1/2 clinical trial for CYWC628 in Australia in the first quarter of 2026 ⁸⁵, the plan to file an IND application for a Phase 1/2 clinical trial for CYMS101 in the United States in the first half of 2026 ⁸⁶, and the filing of a Phase 1/2 Investigational New Drug (IND) application for CYPS317 with the U.S. FDA on December 30, 2025 ⁸⁷. Management also noted that the company received a notification from Nasdaq on December 30, 2025, regarding non-compliance with the Bid-Price Rule, and on February 3, 2026, for non-compliance with the MVLS Rule, but was granted continued listing on the Nasdaq Capital Market by the Panel, subject to satisfying the equity standard of $2.5 million by February 27, 2026, and the Bid Price Rule by April 13, 2026 ⁸⁸.